ES2668272T3 - Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación - Google Patents
Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación Download PDFInfo
- Publication number
- ES2668272T3 ES2668272T3 ES12844799.2T ES12844799T ES2668272T3 ES 2668272 T3 ES2668272 T3 ES 2668272T3 ES 12844799 T ES12844799 T ES 12844799T ES 2668272 T3 ES2668272 T3 ES 2668272T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- nae inhibitor
- administered
- azacitidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555049P | 2011-11-03 | 2011-11-03 | |
| US201161555049P | 2011-11-03 | ||
| PCT/US2012/063382 WO2013067396A2 (en) | 2011-11-03 | 2012-11-02 | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2668272T3 true ES2668272T3 (es) | 2018-05-17 |
Family
ID=48193039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12844799.2T Active ES2668272T3 (es) | 2011-11-03 | 2012-11-02 | Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8980850B2 (OSRAM) |
| EP (1) | EP2773360B1 (OSRAM) |
| JP (2) | JP6231988B2 (OSRAM) |
| KR (1) | KR101987861B1 (OSRAM) |
| CN (1) | CN104245699B (OSRAM) |
| AU (1) | AU2012321106C1 (OSRAM) |
| BR (1) | BR112014010699B1 (OSRAM) |
| CA (1) | CA2854461C (OSRAM) |
| EA (1) | EA028380B1 (OSRAM) |
| ES (1) | ES2668272T3 (OSRAM) |
| GE (1) | GEP20196940B (OSRAM) |
| HK (1) | HK1201733A1 (OSRAM) |
| IL (1) | IL232353B (OSRAM) |
| MA (1) | MA35662B1 (OSRAM) |
| MX (1) | MX357835B (OSRAM) |
| MY (1) | MY176125A (OSRAM) |
| PH (1) | PH12014501001B1 (OSRAM) |
| PL (1) | PL2773360T3 (OSRAM) |
| SG (1) | SG11201401895WA (OSRAM) |
| TN (1) | TN2014000194A1 (OSRAM) |
| TR (1) | TR201807342T4 (OSRAM) |
| UA (1) | UA114414C2 (OSRAM) |
| WO (1) | WO2013067396A2 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1012142A2 (pt) | 2009-05-14 | 2016-03-29 | Millennium Pharm Inc | sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato |
| PH12014500419A1 (en) * | 2011-08-24 | 2020-06-22 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| EP2764866A1 (en) * | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| CA2923752A1 (en) | 2013-05-14 | 2014-11-20 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| JP2016525531A (ja) * | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN103948590A (zh) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | Nedd8激活酶抑制剂及其医药用途 |
| CA3002029A1 (en) * | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| WO2018218119A1 (en) * | 2017-05-25 | 2018-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases |
| EP3684363A4 (en) * | 2017-09-21 | 2021-05-12 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| CA3119781A1 (en) * | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| KR20210151833A (ko) | 2019-03-15 | 2021-12-14 | 풀크럼 쎄러퓨틱스, 인코포레이티드 | Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체 |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
| WO2023242235A1 (en) * | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
| CN115007323B (zh) * | 2022-06-17 | 2024-01-23 | 中南大学 | 一种抑制矿物中黄铁矿浮选的方法 |
| EP4554608A1 (en) * | 2022-07-11 | 2025-05-21 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| SI1848718T1 (sl) | 2005-02-04 | 2012-12-31 | Millennium Pharmaceuticals, Inc. | Inhibitorji E1 aktivacijskih enzimov |
| JP5231251B2 (ja) | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| CA2659894C (en) * | 2006-08-08 | 2018-03-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| CA2742252A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| JP2011513274A (ja) * | 2008-02-26 | 2011-04-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | モルホリニルアントラサイクリン誘導体および脱メチル化剤を含む、抗腫瘍性組合せ |
| AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| EP2307002B1 (en) * | 2008-06-09 | 2013-01-02 | Cyclacel Limited | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
| ES2681529T3 (es) * | 2009-03-23 | 2018-09-13 | Ambit Biosciences Corporation | Métodos de tratamiento utilizando terapia de combinación |
| BRPI1012142A2 (pt) | 2009-05-14 | 2016-03-29 | Millennium Pharm Inc | sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato |
| CN103338753A (zh) | 2011-01-31 | 2013-10-02 | 细胞基因公司 | 胞苷类似物的药物组合物及其使用方法 |
| HK1200716A1 (zh) | 2011-11-01 | 2015-08-14 | 细胞基因公司 | 使用胞苷類似物的口服製劑治療癌症的方法 |
-
2012
- 2012-11-02 MY MYPI2014001239A patent/MY176125A/en unknown
- 2012-11-02 PH PH1/2014/501001A patent/PH12014501001B1/en unknown
- 2012-11-02 EP EP12844799.2A patent/EP2773360B1/en active Active
- 2012-11-02 SG SG11201401895WA patent/SG11201401895WA/en unknown
- 2012-11-02 PL PL12844799T patent/PL2773360T3/pl unknown
- 2012-11-02 ES ES12844799.2T patent/ES2668272T3/es active Active
- 2012-11-02 CN CN201280062112.9A patent/CN104245699B/zh active Active
- 2012-11-02 BR BR112014010699-1A patent/BR112014010699B1/pt not_active IP Right Cessation
- 2012-11-02 CA CA2854461A patent/CA2854461C/en not_active Expired - Fee Related
- 2012-11-02 MX MX2014005323A patent/MX357835B/es active IP Right Grant
- 2012-11-02 US US13/667,641 patent/US8980850B2/en active Active
- 2012-11-02 KR KR1020147014236A patent/KR101987861B1/ko not_active Expired - Fee Related
- 2012-11-02 WO PCT/US2012/063382 patent/WO2013067396A2/en not_active Ceased
- 2012-11-02 HK HK15102294.2A patent/HK1201733A1/xx unknown
- 2012-11-02 EA EA201400539A patent/EA028380B1/ru not_active IP Right Cessation
- 2012-11-02 TR TR2018/07342T patent/TR201807342T4/tr unknown
- 2012-11-02 AU AU2012321106A patent/AU2012321106C1/en not_active Ceased
- 2012-11-02 JP JP2014540146A patent/JP6231988B2/ja active Active
- 2012-11-02 GE GEAP201213483A patent/GEP20196940B/en unknown
- 2012-11-02 UA UAA201405842A patent/UA114414C2/uk unknown
-
2014
- 2014-04-29 IL IL232353A patent/IL232353B/en active IP Right Grant
- 2014-04-30 TN TNP2014000194A patent/TN2014000194A1/en unknown
- 2014-05-26 MA MA37066A patent/MA35662B1/fr unknown
-
2015
- 2015-01-23 US US14/603,717 patent/US20150366886A1/en not_active Abandoned
-
2017
- 2017-10-20 JP JP2017203560A patent/JP2018009035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2668272T3 (es) | Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación | |
| KR101760657B1 (ko) | 약제학적 병용물 | |
| US10786505B2 (en) | Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents | |
| KR102128866B1 (ko) | 오로라 키나제 저해제를 사용하는 암 치료 방법 | |
| US20250064824A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| WO2025070603A1 (ja) | 血液がんの新規併用療法 | |
| BRPI0913231A2 (pt) | combinação farmacêutica |